SLC5A3 and non-small cell lung carcinoma: Treatment with the SLC5A3 inhibitor phlorizin [21, 22] largely inhibited proliferation (EdU-nuclei ratio decreasing, Fig. S2A) and migration (Fig. S2B) in pCan-1 primary NSCLC cells.